Regulatory approvals for AbbVie, J&J bolster the Club investment case
cnbc.com
science
2022-10-20 19:18:47

Regulators in Canada and the U.S. have greenlit new product offerings from two Club pharmaceutical giants, AbbVie (ABBV) and Johnson & Johnson (JNJ) â€” positive developments that validate our investment case in both holdings. AbbVie The news: Canada's national drug regulator, Health Canada, on Thursday approved AbbVie's Skyrizi as a treatment for Crohn's disease, an inflammatory bowel disorder. The regulator had previously cleared Skyrizi to treat active psoriatic arthritis and, for certain adults, severe plaque psoriasis.
